In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Items 301–400 of 673
Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
Lebegge, E., Arnouk, S. M., Bardet, P. M. R., Kiss, M., Raes, G., & Ginderachter, J. A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01395 · Cited by 30
“(150) demonstrated that PD-1-negative TAMs take up anti-PD-1 antibodies that were initially bound to PD-1 CTLs, in an FcR-mediated way.”
BackgroundNanotechnology synergized immunoengineering for cancer
Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 28
Kocikowski, M., Dziubek, K., & Parys, M. (2020) · Cancers · doi:10.3390/cancers12040804 · Cited by 27
“performed an in vivo imaging experiment by tracking fluorescently labelled anti-PD-1 mAbs, MC38 tumour cells, and tumour-associated macrophages (TAMs) injected into mice and following the interactions between those components [62].”
BackgroundFc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies
Zhang, W., Chen, X., Chen, X., Li, J., Wang, H., Yan, X., Zha, H., Ma, X., Zhao, C., Su, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009034 · Cited by 27
Wang, K., Li, C., Huang, P., Liu, H., Yalamandala, B. N., Pan, W., Iao, H. M., & Hu, S. (2024) · Small · doi:10.1002/smll.202406790 · Cited by 27
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
A human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1
Junker, F., Gulati, P., Wessels, U., Seeber, S., Stubenrauch, K., Deak, L. C., Markert, C., Klein, C., Teixeira, P. C., & Kao, H. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24334 · Cited by 28
“This in turn can lead to internalization and removal of the therapeutic antibody, impacting the activation of antigen-presenting cells [40] as well as the local anti-tumor responses [39], which has led to the development of”
BackgroundFujisaki, T., Watanabe, S., Ota, T., Kushiro, K., Sato, Y., Takahashi, M., Ohtsubo, A., Shoji, S., Nozaki, K., Ichikawa, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704475 · Cited by 27
“The blocking effect of PD-1/PD-L1 is generally expected to diminish with the interruption of ICIs because the binding of the anti-PD-1 antibody to PD-1-positive tumor-infiltrating CD8 T cells is transient (20).”
BackgroundTherapeutic Effect of Melittin–dKLA Targeting Tumor-Associated Macrophages in Melanoma
Han, I., Jeong, C., Yang, J., Park, S., Hwang, D., & Bae, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063094 · Cited by 27
“Thus, the enhanced anticancer effects of combination therapy with M2-like TAM-targeting agents on immune checkpoints are repeatedly observed in various cancer models, including lung cancer, colon cancer, melanoma, and breast cancer [48,49].”
Background3D imaging for driving cancer discovery
van Ineveld, R. L., van Vliet, E. J., Wehrens, E. J., Alieva, M., & Rios, A. C. (2022) · The EMBO Journal · doi:10.15252/embj.2021109675 · Cited by 31
“In addition, it has allowed to trace the activity of checkpoint inhibitors in vivo (Arlauckas et al , 2017), thereby revealing that binding dynamics could be prolonged through blockade of Fc c receptors before checkpoint inhibitor administration (Table 1).”
Development and characterization of CD54-targeted immunoPET imaging in solid tumors
Wei, W., Jiang, D., Lee, H. J., Li, M., Kutyreff, C. J., Engle, J. W., Liu, J., & Cai, W. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04784-0 · Cited by 25
Pham, T. D., Spaulding, C., Shields, M. A., Metropulos, A. E., Shah, D. N., Khalafalla, M. G., Principe, D. R., Bentrem, D. J., & Munshi, H. G. (2022) · JCI Insight · doi:10.1172/jci.insight.152731 · Cited by 25
“152731 of anti–PD-1/PD-L1 therapy (18, 19), as targeting TAMs synergizes with anti–PD-1/PD-L1 antibodies to reactivate CD8+ T cells and achieve more potent tumor control (11, 17).”
BackgroundBravo, D. D., Shi, Y., Sheu, A., Liang, W., Lin, W., Wu, Y., Yan, M., & Wang, J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200597 · Cited by 28
Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer
Sivaganesh, V., Promi, N., Maher, S., & Peethambaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052433 · Cited by 27
“Particularly, anti-PD-1 antibodies can successfully block the PD-1–PD-L1 axis but do not have favorable clinical outcomes, possibly due to antibody capture by PD-1 tumor-associated macrophages [91,92].”
BackgroundSoRelle, E. D., Yecies, D. W., Liba, O., Bennett, F. C., Graef, C. M., Dutta, R., Mitra, S., Joubert, L.-M., Cheshier, S., Grant, G. A., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b02656 · Cited by 24
Boosting CAR-T cell therapy with CRISPR technology
Yan, L., Gao, S., Wang, X., Zhou, X., Limsakul, P., & Wu, Y. (2024) · hLife · doi:10.1016/j.hlife.2024.06.002 · Cited by 25
“However, certain limitations are associated with these inhibitors, such as the clearance of antibodies by tumor-associated macrophages (TAMs), adverse effects of repeated treatments, and tumor intrinsic resistance induced by alteration in energy metabolism [102 – 105].”
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 31
“TAMs might weaken antitumor immune responses, probably by sequestering therapeutic anti-PD-1 antibodies from T cells [104].”
BackgroundFranzén, A. S., Raftery, M. J., & Pecher, G. (2022) · Cancers · doi:10.3390/cancers14133178 · Cited by 27
“Furthermore, it has been suggested that TAM can interact with PD1 checkpoint inhibitors by Fcγ-receptor binding, leading to reduced interaction of checkpoint inhibition on CD8+ T cells, which in turn leads to a diminished therapeutic response of PD1 checkpoint inhibitors [57].”
BackgroundA Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
Bu, M. T., Yuan, L., Klee, A. N., & Freeman, G. J. (2022) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0068 · Cited by 25
Self-citationThe role of tumor-associated macrophages in lung cancer
Zhu, R., Huang, J., & Qian, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1556209 · Cited by 39
Dahal, L. N., Huang, C.-Y., Stopforth, R. J., Mead, A., Chan, K., Bowater, J. X., Taylor, M. C., Narang, P., Chan, H. T. C., Kim, J. H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701122 · Cited by 25
“However, this may not be the case with some Abs; anti-PD1 Abs are captured from the T cell surface by macrophages within minutes and this macrophage accrual of anti–PD-1 does not involve transfer of cell membrane components or trogocytosis, which has been described for rituximab (33).”
BackgroundFcγRIIB expressed on CD8+T cells limits responsiveness to PD-1 checkpoint inhibition in cancer
Bennion, K. B., Tariq, M., Wyatt, M. M., Duneton, C., Baecher, K. M., Paulos, C. M., Kudchadkar, R. R., Lowe, M., & Ford, M. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1868 · Cited by 24
Chung, H., Gyu-mi, P., Na, Y. R., Lee, Y., Choi, H., & Seok, S. H. (2024) · Theranostics · doi:10.7150/thno.88917 · Cited by 26
“This is particularly important in a clinical setting because accumulating evidence has revealed that an abundance of TAMs with pro-tumorigenic functions promotes resistance to ICIs [16, 79, 80].”
BackgroundLive Imaging of Innate and Adaptive Immune Responses in the Liver
Li, L., & Zeng, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.564768 · Cited by 28
“Moreover, taking advantage of IVM as an important tool to visualize the in vivo distribution of drugs (150) and adoptively transferred cells (15), it could provide valuable information for optimizing cancer immunotherapy against liver cancers, such as immune checkpoint blockade and adoptive cell therapy.”
MethodMyeloid cell heterogeneity in lung cancer: implication for immunotherapy
Sangaletti, S., Ferrara, R., Tripodo, C., Garassino, M. C., & Colombo, M. P. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02916-5 · Cited by 26
“tumor- associated macrophages via their FcγRs [9].”
Cross Talk Between Macrophages and Cancer Cells in the Bone Metastatic Environment
Batoon, L., & McCauley, L. K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.763846 · Cited by 22
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
A plausible way for excretion of metal nanoparticles via active targeting
Abdellatif, A. A. H. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1752710 · Cited by 23
Masemann, D., Meissner, R., Schied, T., Lichty, B. D., Rapp, U. R., Wixler, V., & Ludwig, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1885778 · Cited by 25
Liu, J., Zhang, B., Cui, Y., Song, H., & Shang, D. (2024) · American Journal of Cancer Research · doi:10.62347/bqfh7352 · Cited by 22
Lepland, A., Peranzoni, E., Haljasorg, U., Asciutto, E. K., Crespí‐Amer, M., Modesti, L., Kilk, K., Lombardía, M., Acosta, G., Royo, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202410288 · Cited by 24
Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2022) · Genes and Immunity · doi:10.1038/s41435-022-00172-w · Cited by 24
“Furthermore, macrophages have been shown to uptake anti-PD-1 antibodies through their Fcγ receptors, thereby limiting efficacy in animal models [38].”
BackgroundYang, R., Huang, S., Huang, C., Fay, N. S., Wang, Y., Putrevu, S., Wright, K., Zaman, M. S., Cai, W., Huang, B. C. B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36942-3 · Cited by 25
Koch, P. D., Rodell, C. B., Köhler, R. H., Pittet, M. J., & Weissleder, R. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2019.12.007 · Cited by 22
“In an effort to further improve checkpoint therapies, a series of recent studies have focused on elucidating cellular mechanisms of action in vivo in order to better understand limited therapeutic efficacy and resistance(Arlauckas et al., 2017; Garris et al., 2018; Moynihan et al., 2016; Ruffell et al., 2014; Spranger…”
BackgroundMethodSelf-citationHernando‐Calvo, A., García‐Álvarez, A., Villacampa, G. J., Ortiz, C., Bodet, D., García‐Patos, V., Recio, J. A., Dienstmann, R., & Muñoz‐Couselo, E. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02420-9 · Cited by 22
Koguchi, Y., Iwamoto, N., Shimada, T., Chang, S., Cha, J., Curti, B. D., Urba, W. J., Piening, B., & Redmond, W. L. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002663 · Cited by 22
Feng, Y., Deyanat‐Yazdi, G., Newburn, K., Potter, S. C., Wortinger, M. A., Ramirez, M., Truhlar, S. M. E., & Yachi, P. P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103339 · Cited by 20
Targeted SPP1 Inhibition of Tumor‐Associated Myeloid Cells Effectively Decreases Tumor Sizes
Kartal, B., Garris, C., Kim, H. S., Köhler, R. H., Carrothers, J. E., Halabi, E. A., Iwamoto, Y., Goubet, A., Xie, Y., Wirapati, P., et al. (2024) · Advanced Science · doi:10.1002/advs.202410360 · Cited by 30
Self-citationÖzdemir, B. C., Bill, R., Okyar, A., Scheiermann, C., Hayoz, S., & Olivier, T. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010644 · Cited by 22
“19 Although a long elimination duration might suggest that the timing of infusion has limited impact on efficacy, other anticancer agents such as oxaliplatin, doxorubicin, and irinotecan demonstrate pronounced chronotoxicity and Open access chronoefficacy, even with their long half-lives and rapid…”
Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance
Zou, J. P., Wang, S., Zhang, Y., Tian, W., Mai, G., Xu, Y., Xiao, W., Graves, E. E., & Wu, F. (2025) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2025.03.12 · Cited by 24
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
Ridder, K. D., Locy, H., Piccioni, E., Zuazo, M., Awad, R. M., Verhulst, S., Bulck, M. V., Vlaeminck, Y. D., Lecocq, Q., Reijmen, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811867 · Cited by 22
Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
Xu, L., Li, B., Pi, C., Zhu, Z., Tao, F., Xie, K., Feng, Y., Xu, X., Yin, Y., Gu, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005447 · Cited by 23
Banerjee, A., Narasimhulu, C. A., & Singla, D. K. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00378.2023 · Cited by 23
Subverted macrophages in the triple-negative breast cancer ecosystem
Shang, L., Zhong, Y., Yao, Y., Liu, C., Wang, L., Zhang, W., Liu, J., Wang, X., & Sun, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115414 · Cited by 23
Levitzki, A., & Klein, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816012116 · Cited by 22
“This effect was abrogated by blocking the Fcγ receptors, suggesting a possible avenue for improving the response to anti–PD-1 (79).”
BackgroundSystems biology approaches to measure and model phenotypic heterogeneity in cancer
Meyer, A. S., & Heiser, L. M. (2019) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2019.09.002 · Cited by 21
Zhang, Z., Liu, L., Ma, C., Cui, X., Lam, R. H. W., & Chen, W. (2021) · Small Methods · doi:10.1002/smtd.202100197 · Cited by 21
Examining Immunotherapy Response Using Multiple Radiotracers
Goggi, J., Hartimath, S. V., Hwang, Y., Tan, Y. X., Khanapur, S., Ramasamy, B., Jiang, L., Yong, F., Cheng, P. K. C., Tan, P. W., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01477-w · Cited by 19
“Furthermore, tumour resident macrophages have been shown to sequester anti-PD-1 antibodies potentially mediating resistance [19].”
BackgroundKatano, I., Hanazawa, A., Otsuka, I., Yamaguchi, T., Mochizuki, M., Kawai, K., Ito, R., Goto, M., Kagawa, T., & Takahashi, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-00641-8 · Cited by 20
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
Cowles, S. C., Sheen, A. M., Santollani, L., Lutz, E. A., Lax, B. M., Palmeri, J. R., Freeman, G. J., & Wittrup, K. D. (2022) · mAbs · doi:10.1080/19420862.2022.2088454 · Cited by 23
“Similar superior performance of anti-PD-1 antibodies with a LALA-PG or other silent Fc isotypes over antibodies with activating isotypes has been previously reported.(36,44,45) The success of the monovalent constructs, combined with the MABS e2088454-9”
BackgroundSelf-citationAntibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors
Guo, Y., Remaily, B., Thomas, J. W., Kim, K., Kulp, S. K., Mace, T. A., Ganesan, L. P., Owen, D. H., Coss, C. C., & Phelps, M. A. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1683 · Cited by 22
Overcoming immune evasion in pancreatic cancer: the combination matters
Michl, P., & Krug, S. (2017) · Gut · doi:10.1136/gutjnl-2017-315443 · Cited by 19
Wang, H., Xia, L., Yao, C., Dong, H., Yang, Y., Li, C., Ji, W., Sun, R., Duan, H., Mengzhou, W., et al. (2021) · Cancer Science · doi:10.1111/cas.15243 · Cited by 20
Naei, V. Y., Tubelleza, R., Monkman, J. H., Sadeghirad, H., Donovan, M. L., Blick, T., Wicher, A. Z., Bodbin, S. E., Viratham, A., Stad, R. K., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06186-y · Cited by 25
Evolution of the protein corona affects macrophage polarization
Yang, H., Lu, S., Wang, S., Liu, L., Zhu, B., Yu, S., Yang, S., & Chang, J. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.09.081 · Cited by 18
Passelli, K., Repáraz, D., Kinj, R., & Herrera, F. G. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae100 · Cited by 20
Gangadaran, P., Onkar, A., Rajendran, R. L., Goenka, A., Oh, J. M., Khan, F., Nagarajan, A. K., Muthu, S., Krishnan, A., Hong, C. M., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00735-9 · Cited by 22
Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development
Messex, J. K., Byrd, C. J., & Liou, G. (2020) · Cells · doi:10.3390/cells9040919 · Cited by 51
Tsukamoto, H., Komohara, Y., & Oshiumi, H. (2021) · Human Cell · doi:10.1007/s13577-021-00514-2 · Cited by 23
“An alternative mechanism that has been reported is that Fc receptors expressed by TAMs strip the anti-PD-1 antibody bound to T cells, which reactivates the PD-1/PD-L1 signal and prevents T-cell activation [59].”
BackgroundLee, Y. J., Lee, J. B., Ha, S., & Kim, H. R. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0044 · Cited by 19
“1, Table 1) (Arlauckas et al., 2017).”
Kang, S. H., & Lee, C. (2021) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0181-8 · Cited by 22
Grell, P., Bořilová, S., Fabián, P., Selingerová, I., Novak, D., Müller, P., Kišš, I., & Vyzula, R. (2023) · Cancers · doi:10.3390/cancers15061901 · Cited by 18
“After administration, the anti-PD-1 antibody binds to tumor-infiltrating T cells at an early stage but is subsequently captured by TAMs due to the presence of Fc γ receptors, ultimately leading to drug failure [39].”
BackgroundImmunotherapy in Head and Neck Cancer: Evidence and Perspectives
Tosoni, A., Franceschi, E., Pasquini, E., Lanese, A., Donini, E., Foschini, M. P., Dall’Olio, D., & Brandes, A. A. (2017) · Immunotherapy · doi:10.2217/imt-2017-0125 · Cited by 17
Single‐Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics
Li, R., Atari, A., Prytyskach, M., Garlin, M. A., Weissleder, R., & Miller, M. A. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23872 · Cited by 18
“mAb transfer did not involve ADCP, but depended on Fc-glycosylation (24).”
BackgroundMethodResultSelf-citationA microfluidic chip for screening high-producing hybridomas at single cell level
Zhang, W., Li, R., Jia, F., Hu, Z., Li, Q., & Wei, Z. (2020) · Lab on a Chip · doi:10.1039/d0lc00847h · Cited by 18
Moody, A. S., Dayton, P. A., & Zamboni, W. C. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.94 · Cited by 26
Sharma, S. K., Suzuki, M., Xu, H., Korsen, J. A., Samuels, Z. V., Guo, H.-F., Nemieboka, B. E., Piersigilli, A., Edwards, K. J., Cheung, N. V., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262383 · Cited by 17
“Recent insights into pharmacologic modulation at the Fc–FcgR axis have made this molecular interaction an important consideration in the development of antibody-based drugs for cancer immunotherapy (16,17,29).”
BackgroundImaging and therapeutic targeting of the tumor immune microenvironment with biologics
Arnouk, S. M., Groof, T. W. M. D., & Ginderachter, J. A. V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114239 · Cited by 17
FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis
Lindorfer, M. A., & Taylor, R. P. (2022) · Antibodies · doi:10.3390/antib11030045 · Cited by 19
“However, in vitro experiments indicated there was no evidence for the transfer of membrane fragments or PD-1 antigen from these donor cells to macrophages, thus precluding the strict identification of this process as trogocytosis [95].”
BackgroundLiu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025) · Journal of Cancer · doi:10.7150/jca.108163 · Cited by 18
“(3) Hijacking anti-PD-1 antibody: TAM can capture anti-PD-1 antibody through binding to the Fc region of the antibody with the FcγR expressed on the macrophages [80].”
Lu, G., Hickey, J. W., Haist, M., Qin, X., Zhao, D. E., Naveed, A., Forgó, E., Baertsch, M., Mani, L., Rovira‐Clavé, X., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03152-x · Cited by 22
“This aligns with prior findings that macrophages can interact with antibody–drug conjugates to release the cytotoxic payload and result in bystander killing 40 or capture PD1 inhibitors to inhibit their binding to T cells and cause drug resistance 41 .”
Pizzurro, G. A., Liu, C., Bridges, K., Alexander, A. F., Huang, A., Baskaran, J. P., Ramseier, J. Y., Bosenberg, M., Mak, M., & Miller‐Jensen, K. (2021) · Cancers · doi:10.3390/cancers13184579 · Cited by 16
“TAMs have also been associated with resistance to checkpoint inhibitors treatment [29].”
BackgroundIntratumoral Anti-PD-1 Nanoformulation Improves Its Biodistribution
Badiee, P., Maritz, M. F., Dmochowska, N., Cheah, E., & Thierry, B. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c22479 · Cited by 16
Highly Active Myeloid Therapy for Cancer
Fredrich, I. R., Halabi, E. A., Köhler, R. H., Ge, X., Garris, C., & Weissleder, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c08034 · Cited by 18
Self-citationTaylor, C., Patterson, K. M., Friedman, D., Bacot, S. M., Feldman, G. M., & Wang, T. (2024) · Cancers · doi:10.3390/cancers16173071 · Cited by 17
Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
Wang, S., Nie, F., Yin, Q., Tian, H., Gong, P., Ju, J., Liu, J., Yang, P., & Yang, C. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03865-5 · Cited by 18
“Macrophages could capture the administrated anti-PD-1 antibody from the T cell surface within minutes and affect the outcomes of anti-PD-1 treatment depending on their Fcγ-receptors (FcγRs) [37], implying that FcγRs on macrophages are also immunosuppressive factors.”
Understanding the In Vivo Fate of Advanced Materials by Imaging
Li, R., Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910369 · Cited by 20
Self-citationYang, W., Zhang, M., Zhang, J., Liu, Y., Ning, J., Yang, J., Zhang, Z., Hou, L., & Chen, X. S. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101492 · Cited by 17
Sow, H. S., Benonisson, H., Breukel, C., Visser, R., Verhagen, O. J. H. M., Bentlage, A. E. H., Brouwers, C. M., Claassens, J. W. C., Linssen, M. M. L., Camps, M. G. M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31899 · Cited by 18
“preclinical studies have revealed that interaction with its Fc part is detrimental to the therapeutic efficacy of anti-PD-1 mAb, by facilitating macrophages to deplete PD1 effector T cells(10) or to remove this mAb from T cells.(26) This illustrates that it is important to understand the impact of the interaction with…”
BackgroundInsights into intercellular receptor-ligand binding kinetics in cell communication
An, C., Wang, X., Song, F., Hu, J., & Li, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.953353 · Cited by 16
Klein, S., Schulte, A., Arolt, C., Tolkach, Y., Reinhardt, H. C., Buettner, R., & Quaas, A. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100272 · Cited by 18
Zhang, H., Lu, X., Lu, B., Gullo, G., & Chen, L. (2024) · Future Oncology · doi:10.2217/fon-2023-0658 · Cited by 18
“First, in addition to CD8 topology, the distributions of other cell types in the TME should be con-1208 sidered, as it has been shown that tumor-associated macrophages [35 , 36] , myeloid-derived suppressor cells [37–40] and regulatory Tregs [41] are inevitably involved in immune evasion in the TME.”
BackgroundPreclinical comparison of prolgolimab, pembrolizumab and nivolumab
Gordeev, A., Vaal, A., Puchkova, M., Smirnova, I., Doronin, A., Znobishcheva, A., Zhmudanova, D., Aleksandrov, A., Sukchev, M., Imyanitov, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72118-3 · Cited by 19
Xu, J., Li, Z., Tong, Q., Zhang, S., Fang, J., Wu, A., Wei, G., Zhang, C., Yu, S., Zheng, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55876-0 · Cited by 17
Diving into the mechanism of action of tumor immunotherapies with intravital imaging*
Bousso, P. (2021) · Immunological Reviews · doi:10.1111/imr.13032 · Cited by 15
Probing immune infiltration dynamics in cancer by in vivo imaging
Ng, T. S. C., Allen, H. H., Rashidian, M., & Miller, M. A. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102117 · Cited by 15
Self-citationIlieva, K. M., Fazekas, J., Achkova, D., Dodev, T. S., Mele, S., Crescioli, S., Bax, H. J., Cheung, A., Karagiannis, P., Corrêa, I., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01112 · Cited by 16
“In some cases, effector cell engagement may not always be desirable, may impede Fab-mediated effects or bear safety hazards if intact Fc-mediated effector functions are retained (22, 23, 25, 75).”
BackgroundAoki, T., Nishida, N., & Kudo, M. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211056853 · Cited by 15
Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful
Szulc-Kiełbik, I., & Kiełbik, M. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_4 · Cited by 14
Li, J., Wang, Y., Jin, W., & Shen, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s294253 · Cited by 14
Xu, X., Li, R., Dong, R., Yang, Y., Wang, H., Cheng, J., Liu, Y., & Ye, J. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0030 · Cited by 17
“0 International License microenvironment exhibit primarily M2-type characteristics, recruit immunosuppressive cells through the production of immunosuppressive cytokines and chemokines, and induce tumor cells to express PD-L1, thereby forming an immunosuppressive network and ultimately promoting tumor immune escape [8…”
BackgroundMolecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
Jiang, X., Li, L., Li, Y., & Li, Q. (2019) · Journal of Cancer · doi:10.7150/jca.26481 · Cited by 17
Mitchell, L., Yagiz, K., Hofacre, A., Viaud, S., Munday, A. W., Espinoza, F. L., Mendoza, D., Rodriguez-Aguirre, M. E., Bergqvist, S., Haghighi, A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26785 · Cited by 14
“A possible explanation of this phenomenon is suggested by a recent report which revealed that bound anti-PD-1 antibody on T cells can be phagocytosed by PD-1-negative tumor associated macrophages via interaction between the antibody Fc glycan and FcγR on the macrophages, limiting antibody retention in the TME and redu…”
BackgroundKang, T. H., & Jung, S. T. (2020) · Biomolecules · doi:10.3390/biom10030382 · Cited by 14
“therapeutic efficacy, compared to that having constant region of IgG4 [100].”
BackgroundPeng, X., Wang, Y., Zhang, J., Zhang, Z., & Qi, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1288273 · Cited by 18
Applications of Intravital Imaging in Cancer Immunotherapy
Deng, D., Hao, T., Lu, L., Yang, M., Zeng, Z., Lovell, J. F., Liu, Y., & Jin, H. (2024) · Bioengineering · doi:10.3390/bioengineering11030264 · Cited by 13
“In another example, in vivo imaging was used by Arlauckas SP et al. to discover that the Fc receptor on the surface of myeloid cells was a key factor affecting the therapeutic effect of PD-1 inhibition [81].”
Yan, L., Wen, Z., Yang, Y., Liu, A., Li, F., Zhang, Y., Yang, C., Li, Y., & Zhang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117551 · Cited by 13
The application and mechanism of PD pathway blockade for cancer therapy
Wang, X., Huang, S., Zhang, Y., Zhu, L., & Wu, X. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135187 · Cited by 13
Donthireddy, L., Vonteddu, P., Murthy, T., Kwak, T., Eraslan, R.-N., Podojil, J. R., Elhofy, A., Boyne, M. T., Puisis, J., Veglia, F., et al. (2022) · Journal of Cancer · doi:10.7150/jca.69338 · Cited by 17
“The presence of MDSCs in peripheral blood and TAMs in the TME predicts poor survival and is associated with low rates of response and development of resistance to immune-targeted therapies such as immune checkpoint inhibitors [7,14-18].”
BackgroundMacrophage Origin, Metabolic Reprogramming and IL-1β Signaling: Promises and Pitfalls in Lung Cancer
Guilbaud, E., Gautier, E. L., & Yvan‐Charvet, L. (2019) · Cancers · doi:10.3390/cancers11030298 · Cited by 19
“The group of Pittet identified an anti-PD-1 steal mechanism by TAMs which depends on FcγRIIb/III receptors and limits binding and activation to tumor-killing T-cells (Figure 3) [281].”
Background
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.